|
|
C Gauthier, G Tavernier, F Charpentier, D Langin, H Le Marec
J Clin Invest. 1996;
98(2):556
doi:10.1172/JCI118823
Abstract |
Full text
| PDF

B
eta3-adrenoceptors are involved in metabolism, gut relaxation, and vascular vasodilation. However, their existence and role in the human heart have not been documented. We investigated the effects of several beta-adrenoceptor agonists and antagonists on the mechanical properties of ventricular endomyocardial biopsies. In the presence of nadolol, a beta1- and beta2-adrenoceptor antagonist, isoprenaline produced consistent negative inotropic effects. Similar negative inotropic effects also resulted from the action of beta3-adrenoceptor agonists with an order of potency: BRL 37344 > SR 58611 approximately CL 316243 > CGP 12177. The dose-response curve to BRL 37344-decreasing myocardial contractility was not modified by pretreatment with nadolol, but was shifted to the right by bupranolol, a nonselective beta-adrenoceptor antagonist. Beta3-adrenoceptor agonists also induced a reduction in the amplitude and an acceleration in the repolarization phase of the human action potential. Beta3-adrenoceptor transcripts were detected in human ventricle by a polymerase chain reaction assay. These results indicate that: (a) beta3-adrenoceptors are present and functional in the human heart; and (b) these receptors are responsible for the unexpected negative inotropic effects of catecholamines and may be involved in pathophysiological mechanisms leading to heart failure.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(117)
| Title and authors |
Publication |
Year |
Comprehensive Physiology
Masayasu Hiraoka
|
Comprehensive Physiology
|
2011 |
Are there functional β3-adrenoceptors in the human heart?
Martin C Michel, Sian E Harding, Richard A Bond
|
British Journal of Pharmacology
|
2011 |
Human atrial β1L-adrenoceptor but not β3-adrenoceptor activation increases force and Ca2+ current at physiological temperature
Torsten Christ, Peter Molenaar, Paul M Klenowski, Ursula Ravens, Alberto J Kaumann
|
British Journal of Pharmacology
|
2011 |
Safety of perioperative β-blocker use: how do β-blockers compare in terms of side effects?
Niels JC Ravensbergen, Michiel T Voute, Don Poldermans
|
Expert Opin. Drug Saf.
|
2011 |
Activation of β<sub>3</sub>-Adrenoceptor Promotes Rapid Pacing-Induced Atrial Electrical Remodeling in Rabbits
Jiahui Yu, Weimin Li, Yue Li, Jing Zhao, Lanfeng Wang, Deli Dong, Zhenwei Pan, Baofeng Yang
|
Cell Physiol Biochem
|
2011 |
The Role of β-adrenergic Receptors in the Cardioprotective Effects of Beta-Preconditioning (βPC)
Ruduwaan Salie, Johannes A. Moolman, Amanda Lochner
|
Cardiovasc Drugs Ther
|
2011 |
Pharmacogenomics of β-Adrenergic Receptor Physiology and Response to β-Blockade :
Peter von Homeyer, Debra A. Schwinn
|
Anesthesia & Analgesia
|
2011 |
Beta3-Adrenoreceptor Stimulation Ameliorates Myocardial Ischemia-Reperfusion Injury Via Endothelial Nitric Oxide Synthase and Neuronal Nitric Oxide Synthase Activation
Juan P. Aragón, Marah E. Condit, Shashi Bhushan, Benjamin L. Predmore, Sandeep S. Patel, D. Bennett Grinsfelder, Susheel Gundewar, Saurabh Jha, John W. Calvert, Lili A. Barouch
|
Journal of the American College of Cardiology
|
2011 |
Pharmacology of the Cardiovascular System
Marc G. Sturgill, Michael Kelly, Daniel A. Notterman
|
Pediatric Critical Care
|
2011 |
Modulation of β-adrenergic receptor signaling in heart failure and longevity: targeting adenylyl cyclase type 5
David Ho, Lin Yan, Kousaku Iwatsubo, Dorothy E. Vatner, Stephen F. Vatner
|
Heart Fail Rev
|
2010 |
|